Company intelligence / Profile preview
Annexon Biosciences
Brisbane, California, United States
- Ownership
- Public · ANNX
- Employees
- ~51
- Development stage
- Other
01
Overview
ANX005 completed enrollment in its first Phase 3 pivotal program for Guillain-Barré Syndrome in 40 years[1]. ANX007 demonstrated statistically significant, dose-dependent preservation of visual function in Phase 2 trial for geographic atrophy, with Phase 3 data expected in 2H26[1]. ANX1502 achieved target pharmacokinetics in Phase 1 healthy volunteer study[1].
- Therapeutic areas
- OphthalmologyHematologyImmunologyNeurology
- Modalities
- Monoclonal antibodyMonoclonal antibody fragmentSmall molecule
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Annexon Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Annexon Biosciences.